Jazz Pharmaceuticals plc’s filing revealed that its Officer COZADD BRUCE C acquired Company’s shares for reported $1.1 million on Aug 01 ’25. In the deal valued at $121.80 per share,9,000 shares were bought.
Then, COZADD BRUCE C sold 1,000 shares, generating $107,630 in total proceeds. Upon selling the shares at $107.63, the Chairman & CEO now owns 436,973 shares.
Before that, COZADD BRUCE C bought 1,000 shares. Jazz Pharmaceuticals plc shares valued at $107,630 were divested by the Officer at a price of $107.63 per share.
Deutsche Bank initiated its Jazz Pharmaceuticals plc [JAZZ] rating to a Buy in a research note published on July 15, 2025; the price target was $152. A number of analysts have revised their coverage, including UBS’s analysts, who increased its forecast for the stock in early March from “a Neutral” to “a Buy”. Cantor Fitzgerald also remained covering JAZZ and has decreased its forecast on February 26, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Wells Fargo revised its rating on February 13, 2025. It rated JAZZ as “an Overweight” which previously was an “an Equal weight”.
Price Performance Review of JAZZ
On Monday, Jazz Pharmaceuticals plc [NASDAQ:JAZZ] saw its stock jump 0.50% to $116.1. Over the last five days, the stock has lost -1.09%. Jazz Pharmaceuticals plc shares have risen nearly 5.31% since the year began. Nevertheless, the stocks have fallen -5.72% over the past one year.
How much short interest is there in Jazz Pharmaceuticals plc?
A steep rise in short interest was recorded in Jazz Pharmaceuticals plc stocks on 2025-07-15, dropping by -0.1 million shares to a total of 5.73 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 5.83 million shares. There was a decline of -1.79%, which implies that there is a negative sentiment for the stock.
